VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Gershenson on Evolution of Targeted Therapies for Rare Gynecologic Malignancies

David M. Gershenson, MD
Published: Thursday, Feb 11, 2016



David M. Gershenson, MD, professor, Obstetrics, Gynecology and Reproductive Sciences, The University of Texas MD Anderson Cancer Center, discusses the evolution of targeted therapies for patients with rare gynecologic malignancies.

Much progress has been made in understanding the molecular biology of and development of therapies for ovarian cancer over the last decade, Gershenson explains. In recurrent low-grade serous carcinoma, MEK inhibitors have shown to be effective. Other genes involved in the pathogenesis may be targetable, he adds. Additionally, bevacizumab has demonstrated efficacy in serous carcinoma.

In clear cell carcinoma of the endometrium, the PI3K/AKT/mTOR pathway is abnormal in a significantly high number of patients, demonstrating another area that may be targetable. Researchers are currently working to develop novel agents and combine them with translational research endpoints.



David M. Gershenson, MD, professor, Obstetrics, Gynecology and Reproductive Sciences, The University of Texas MD Anderson Cancer Center, discusses the evolution of targeted therapies for patients with rare gynecologic malignancies.

Much progress has been made in understanding the molecular biology of and development of therapies for ovarian cancer over the last decade, Gershenson explains. In recurrent low-grade serous carcinoma, MEK inhibitors have shown to be effective. Other genes involved in the pathogenesis may be targetable, he adds. Additionally, bevacizumab has demonstrated efficacy in serous carcinoma.

In clear cell carcinoma of the endometrium, the PI3K/AKT/mTOR pathway is abnormal in a significantly high number of patients, demonstrating another area that may be targetable. Researchers are currently working to develop novel agents and combine them with translational research endpoints.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x